[
    [
        {
            "time": "2018-01-01",
            "original_text": "Eli Lilly’s Cardiovascular Products Portfolio in 3Q17",
            "features": {
                "keywords": [
                    "Cardiovascular",
                    "Products",
                    "Portfolio",
                    "3Q17"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Eli Lilly’s Cardiovascular Products Portfolio in 3Q17",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Eli Lilly’s Endocrine Product Portfolio in 3Q17",
            "features": {
                "keywords": [
                    "Endocrine",
                    "Product",
                    "Portfolio",
                    "3Q17"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Eli Lilly’s Endocrine Product Portfolio in 3Q17",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Eli Lilly & Co. breached its 50 day moving average in a Bearish Manner : LLY-US : January 1, 2018",
            "features": {
                "keywords": [
                    "breached",
                    "50 day moving average",
                    "Bearish",
                    "LLY-US"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly & Co. breached its 50 day moving average in a Bearish Manner : LLY-US : January 1, 2018",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Eli Lilly’s New Products Portfolio in 3Q17",
            "features": {
                "keywords": [
                    "New",
                    "Products",
                    "Portfolio",
                    "3Q17"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Eli Lilly’s New Products Portfolio in 3Q17",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        }
    ]
]